A new drug candidate in the fight against cancer

Press release: SATT Nord and Apmonia Therapeutics have entered into agreements in which Apmonia Therapeutics has been granted an exclusive worldwide license for the development and commercialization of the innovative anti-cancer immunotherapy (TAX2 peptide).

#immunotherapy #fightcancer #peptide

more :

Share this post

Share on facebook
Share on linkedin
Share on twitter
Share on email

More to explore

Overall News

Welcome to Reims 2019

Apmonia Therapeutics is honored and delighted to have been elected as most promising #startup of the year during “Welcome to Reims” event last week. We